MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, P.R. China.
CAS Key Laboratory of Regenerative Biology, Joint School of Life Sciences, Hefei Institute of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Medical University, Guangzhou, P.R. China.
Cancer Res. 2022 Jul 5;82(13):2431-2443. doi: 10.1158/0008-5472.CAN-21-3910.
Micropeptides are a recently discovered class of molecules that play vital roles in various cellular processes, including differentiation, proliferation, and apoptosis. Here, we sought to identify cancer-associated micropeptides and to uncover their mechanistic functions. A micropeptide named short transmembrane protein 1 (STMP1) that localizes at the inner mitochondrial membrane was identified to be upregulated in various cancer types and associated with metastasis and recurrence of hepatocellular carcinoma. Both gain- and loss-of-function studies revealed that STMP1 increased dynamin-related protein 1 (DRP1) activation to promote mitochondrial fission and enhanced migration of tumor cells. STMP1 silencing inhibited in vivo tumor metastasis in xenograft mouse models. Overexpression of STMP1 led to redistribution of mitochondria to the leading edge of cells and enhanced lamellipodia formation. Treatment with a DRP1 inhibitor abrogated the promotive effect of STMP1 on mitochondrial fission, lamellipodia formation, and tumor cell migration in vitro and metastasis in vivo. Furthermore, STMP1 interacted with myosin heavy chain 9 (MYH9), the subunit of nonmuscle myosin II, and silencing MYH9 abrogated STMP1-induced DRP1 activation, mitochondrial fission, and cell migration. Collectively, this study identifies STMP1 as a critical regulator of metastasis and a novel unit of the mitochondrial fission protein machinery, providing a potential therapeutic target for treating metastases.
This study identifies the mitochondrial micropeptide STMP1 as a regulator of metastasis that promotes mitochondrial fission and tumor cell migration via DRP1 and MYH9.
微肽是一类新发现的分子,在细胞分化、增殖和凋亡等多种细胞过程中发挥重要作用。在这里,我们试图鉴定与癌症相关的微肽,并揭示它们的机制功能。一种名为短跨膜蛋白 1(STMP1)的微肽被鉴定为在多种癌症类型中上调,与肝癌的转移和复发相关。功能获得和功能丧失研究均表明,STMP1 增加了动力相关蛋白 1(DRP1)的激活,以促进线粒体裂变,并增强肿瘤细胞的迁移。STMP1 沉默抑制了异种移植小鼠模型中的体内肿瘤转移。STMP1 的过表达导致线粒体重新分布到细胞的前缘,并增强了伪足的形成。DRP1 抑制剂的处理消除了 STMP1 对体外线粒体裂变、伪足形成和肿瘤细胞迁移以及体内转移的促进作用。此外,STMP1 与肌球蛋白重链 9(MYH9)相互作用,MYH9 是非肌肉肌球蛋白 II 的亚基,沉默 MYH9 消除了 STMP1 诱导的 DRP1 激活、线粒体裂变和细胞迁移。总之,这项研究鉴定了 STMP1 作为转移的关键调节剂,以及线粒体裂变蛋白机器的一个新单元,为治疗转移提供了一个潜在的治疗靶点。
本研究鉴定了线粒体微肽 STMP1 作为转移的调节剂,通过 DRP1 和 MYH9 促进线粒体裂变和肿瘤细胞迁移。